- Home
- CLDX vs DVAX Comparison
CLDX vs DVAX Comparison
Compare CLDX & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- DVAX
- Stock Information
- Founded
- CLDX N/A
- DVAX 1996
- Country
- CLDX United States
- DVAX United States
- Employees
- CLDX N/A
- DVAX N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- DVAX Health Care
- Exchange
- CLDX Nasdaq
- DVAX Nasdaq
- Market Cap
- CLDX 1.4B
- DVAX 1.3B
- IPO Year
- CLDX 2008
- DVAX 2004
- Fundamental
- Price
- CLDX $22.08
- DVAX $10.12
- Analyst Decision
- CLDX Strong Buy
- DVAX Buy
- Analyst Count
- CLDX 9
- DVAX 4
- Target Price
- CLDX $46.13
- DVAX $26.50
- AVG Volume (30 Days)
- CLDX 1.5M
- DVAX 1.8M
- Earning Date
- CLDX 08-07-2025
- DVAX 08-07-2025
- Dividend Yield
- CLDX N/A
- DVAX N/A
- EPS Growth
- CLDX N/A
- DVAX N/A
- EPS
- CLDX N/A
- DVAX N/A
- Revenue
- CLDX $5,790,000.00
- DVAX $316,268,000.00
- Revenue This Year
- CLDX N/A
- DVAX $23.23
- Revenue Next Year
- CLDX N/A
- DVAX $16.57
- P/E Ratio
- CLDX N/A
- DVAX N/A
- Revenue Growth
- CLDX N/A
- DVAX 26.66
- 52 Week Low
- CLDX $14.40
- DVAX $9.22
- 52 Week High
- CLDX $47.00
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- CLDX 47.99
- DVAX 39.76
- Support Level
- CLDX $21.34
- DVAX $10.27
- Resistance Level
- CLDX $23.27
- DVAX $11.45
- Average True Range (ATR)
- CLDX 1.54
- DVAX 0.30
- MACD
- CLDX -0.15
- DVAX -0.07
- Stochastic Oscillator
- CLDX 33.75
- DVAX 5.67
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.